Brain choline acetyltransferase and mental function in Alzheimer disease

Archives of Neurology

Volumn 56, Issue 9, 1999, Pages 1121-1123

  Baskin, David S ^a   Browning, Jeffrey L ^a   Pirozzolo, Francis J ^a   Korporaal, Sonja ^a   Baskin, Juli A ^a   Appel, Stanley H ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE ACETYLTRANSFERASE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN BIOPSY; BRAIN FUNCTION; BRAIN LEVEL; BRAIN VENTRICLE PERITONEUM SHUNT; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMPLANTATION; INFUSION PUMP; INTELLIGENCE TEST; MALE; MENTAL FUNCTION; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; BIOPSY; BRAIN; CHOLINE O-ACETYLTRANSFERASE; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS;

EID: 0032887166     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.9.1121     Document Type: Article

References (26)

1. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile changes in the cerebral gray matter of elderly subjects. Br J Psychiatry. 1968;114:797-811.
2. Wilcock GK, Esiri MM. Plaques, tangles and dementia. J Neurol Sci. 1982;56:343-356.
3. Faulstich ME. Brain imaging in dementia of the Alzheimer type. Intern J Neurosci. 1991; 57:39-49.
4. Gottfries C-G, Adolfsson R, Aquilonius S-M, et al. Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol Aging. 1983;4:261-271.
5. Quirion R, Martel JC, Robitaille Y, et al. Neurotransmitler and receptor deficits in senile dementia of the Alzheimer type. Can J Neurol Sci. 1986;13:503-510.
6. Martignoni E, Costa A, Sinforiani E, et al. The brain as a target for adrenocortical steroids: cognitive implications. Psychoneuroendocrinology. 1992;17:343-354.
7. Deshmukh VD, Deshmukh SV. Stress-adaptation failure hypothesis of Alzheimer's disease. Med Hypotheses. 1990;32:293-295.
8. Adolfsson R, Gottfries CG, Roos BE, Winblad B. Changes in the catecholamines in patients with dementia of the Alzheimer type. Br J Psychiatry. 1979;135:216-223.
9. Pascual J, Grijalba B, García-Sevilla JA, Zarranz JJ, Pazos A. Loss of high-affinity α2-adrenoceptors in Alzheimer's disease: an autoradiographic study in frontal cortex and hippocampus. Neurosci Lett. 1992;142:36-40.
10. Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408-417.
11. Perry EK. The cholinergic hypothesis. Br Med Bull. 1986;42:63-69.
12. Kumar V, Durai NB, Jobe T. Pharmacologic management ot Alzheimer's disease. Clin Geriatr Med. 1998;14:129-146.
13. Perry EK, Perry RH. Human brain neurochemistry: some postmortem problems. Life Sci. 1983;33:1733-1743.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease. Neurology. 1984;34:939-944.
15. Schrier BK, Shuster L. A simplified radio-chemical assay for choline acetyltransferase. J Neurochem. 1967;14:977-985.
16. Lowry OH, Rosebrough NJ, Farr LA, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:265-275.
17. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzhemier's disease: Donepezil Study Group. Neurology. 1998;50:136-145.
18. Asthana S, Raffaele KC, Berardi A, et al. Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine. Alzheimer Dis Assoc Disord. 1995; 9:223-232.
19. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol. 1997;54:465-473.
20. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease: The Tacrine Study Group. JAMA. 1992;268:2523-2529.
21. DeKosky ST, Harbaugh RE, Schmidt FA, et al. The Intraventricular Bethanecol Study Group. Ann Neurol. 1992;32:625-632.
22. Lehéricy S, Hirsch ÉC, Cervera-Piérot P, et al. Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease. J Comp Neurol. 1993;330:15-31.
23. Reinikainen KJ, Riekkinen PJ, Paljärvi L, et al. Cholinergic deficit in Alzheimer's disease: a study based on CSF and autopsy data. Neurochem Res. 1988;13:135-146.
24. Lawrence AD, Sahakian BJ. The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems. Neurochem Res. 1998;23:787-794.
25. Robbins TW, McAlonan G, Muir JL, Everitt BJ. Cognitive enhancers in theory and practice. Behav Brain Res. 1997;83:15-23.
26. McDonald MP, Overmier JB. Present imperfect: a critical review of animal models of the mnemonic impairments in Alzheimer's disease. Neurosci Biobehav Rev. 1998;22:99-120.